阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察

doi:10.3969/j.issn.1672-5069.2014.03.025

Abstract

Chai Yanyun, Li Jianguo, Zhang Xinlong. Clinical efficacies and adverse reactions of adefovir and entecavir in the treatment of HBeAg positive patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 307-309.

References

[1] DiM arco V,Craxi A.Chronic hepatitis B:who to treat and which choice of treatment Expert Rev Anti Infect Ther,2009,7（3）:281-291.
[2] 徐俊斌,黄斯英. 阿德福韦酯治疗HBeAg阴性慢性乙型肝炎22例临床观察. 实用肝脏病杂志,2008,11（3）：183.
[3] 沙小莹,王虹. 干扰素-2b联合阿德福韦酯治疗慢性乙型肝炎30例. 陕西医学杂志,2009,38（8）:60.
[4] Tenney DJ,Rose RE,Baldick CJ,et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology,2009,49（5）：1503-1514.
[5] 张倩,梁红霞,陈奎生,等.恩替卡韦和阿德福韦治疗乙型肝炎5年疗效比较. 临床医学,2013,33（7）：42-44.
[6] Zoulim F,Chemin I. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett,2009,10（1）:1-8.
[7] Lu FM,Zhuang H. Management of hepatitis B in China. Chin Med J,2009,122（1）:3-4.
[8] 谢琴秀,许家璋,郜玉峰,等. 拉米夫定治疗后发生YMDD变异的相关因素分析. 中华传染病杂志,2005,23（5）:314-317.
[9] Marcellin P,Chang TT,Lim SG,et al. Long term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B.Hepatology,2008,48（3）:750-758.
[10] 姚光弼,陈成伟,陆纬伦,等. 恩替卡韦和拉米夫定治疗慢性乙型肝炎二年病毒学、血清学和生化结果的随机对比研究. 肝脏,2008,13（1）:2-6.
[11] Chang TT,Gish RG,de Man R,et al.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med,2006,354（10）:1001-1010.
[12] 郭翔. 恩替卡韦联合安络化纤丸治疗慢性乙型肝炎56例. 实用肝脏病杂志,2011,14（6）,444-445.
[13] 刘政芳,潘晨,高海兵,等. 恩替卡韦联合血浆置换治疗慢性乙型重型肝炎临床观察. 实用肝脏病杂志,2009,12（5）,371-372.
[14] 杨小昂,窦明,陈宏涛,等.恩替卡韦治疗慢性乙型肝炎初治患者临床疗效观察. 临床荟萃,2011,26（10）：898-900.
[15] 马建明.恩替卡韦治疗HBeAg阳性慢性乙型肝炎早期ALT升高的临床特征. 实用肝脏病杂志,2010,13（5）,371-372.

Clinical efficacies and adverse reactions of adefovir and entecavir in the treatment of HBeAg positive patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.